Immune cell therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT03029338
First seen Feb 15, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This study tested a new treatment using specially engineered immune cells (CD19 CAR T cells) in 20 adults with relapsed or hard-to-treat B-cell lymphoma. The cells were given in three doses over three days. The main goal was to check safety and see how well the treatment worked. This early-phase trial helps pave the way for better therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.